CNCR
Range Cancer Therapeutics Index ETF
Set alert
9.02 USD +0.14 +1.58%
9.02 Day range 9.41
11.86 52-week range 17.96
- YTD
- -26.73%
- 1 year
- -34.26%
- Open
- 9.41
- Prev close
- 8.88
- Mkt cap
- 7.04M
- Vol
- 3.08K
- Avg vol
- 3.41K
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 9.02
- High
- 9.41
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 14.25
- 200-d avg
- 14.74
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 14.25
- 200-day average
- 14.74
About Range Cancer Therapeutics Index ETF
The index was established in 2023 by Range Fund Holdings and tracks the performance of a portfolio of U.S. exchange-listed pharmaceutical or biotechnology stocks or American Depositary Receipts (“ADRs”) with a market capitalization of more than $250 million. The advisor attempts to invest all, or substantially all, of its assets in the component securities that make up the index. Under normal circumstances, at least 80% of the fund’s total assets will be invested in the component securities of the index.
News
- Disruptive Theme of the Week – Breakthroughs in Medicine
- The Zacks Analyst Blog SFYX, CNCR, FXN and DIV
- 4 Solid ETFs Under $20 for Your Portfolio
- 5 ETFs That Led the Rebound on Monday
- Best-Performing ETF Areas of Past Week
- 5 Top-Ranked ETFs to Buy at a Bargain
- Best ETFs of Last Week
- 5 Top ETFs of Last Week
- Last Week in ETFs: 8 New Defined Outcome ETFs Debut
- 3 Top-Ranked ETFs Under $20 for Your Portfolio
Your note
Sign in to keep a note on CNCR — it syncs with the Stock Master app.